Fiera Capital Corp Decreases Holdings in Novo Nordisk A/S (NYSE:NVO)

Fiera Capital Corp reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 7.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 2,807 shares of the company’s stock after selling 225 shares during the period. Fiera Capital Corp’s holdings in Novo Nordisk A/S were worth $334,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S in the third quarter worth $42,000. Stiles Financial Services Inc increased its holdings in Novo Nordisk A/S by 1.0% in the 3rd quarter. Stiles Financial Services Inc now owns 44,962 shares of the company’s stock worth $5,354,000 after acquiring an additional 436 shares during the last quarter. Winthrop Advisory Group LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $234,000. Lewis Asset Management LLC lifted its holdings in Novo Nordisk A/S by 3.4% during the third quarter. Lewis Asset Management LLC now owns 5,472 shares of the company’s stock valued at $652,000 after purchasing an additional 182 shares during the last quarter. Finally, Channel Wealth LLC boosted its position in Novo Nordisk A/S by 15.6% during the third quarter. Channel Wealth LLC now owns 57,353 shares of the company’s stock worth $6,829,000 after purchasing an additional 7,756 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.4 %

Shares of NYSE NVO opened at $107.20 on Monday. The business has a 50-day moving average of $121.42 and a 200-day moving average of $130.31. The firm has a market capitalization of $481.06 billion, a price-to-earnings ratio of 34.69, a PEG ratio of 1.48 and a beta of 0.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15.

Analyst Ratings Changes

NVO has been the topic of several research reports. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets reduced their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.